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SUMMARY
Mendelian models can predict who carries an inherited deleterious mutation of known disease genes
based on family history. For example, the BRCAPRO model is commonly used to identify families who
carry mutations of BRCA1 and BRCA2, based on familial breast and ovarian cancers. These models
incorporate the age of diagnosis of diseases in relatives and current age or age of death. We develop a
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2 H. A. KATKI ET. AL
rigorous foundation for handling multiple diseases with censoring. We prove that any disease unrelated
to mutations can be excluded from the model, unless it is sufficiently common and dependent on a
mutation-related disease time. Furthermore, if a family member has a disease with higher probability
density among mutation carriers, but the model does not account for it, then the carrier probability
is deflated. However, even if a family only has diseases the model accounts for, if the model excludes
a mutation-related disease, then the carrier probability will be inflated. In light of these results, we
extend BRCAPRO to account for surviving all non-breast/ovary cancers as a single outcome. The
extension also enables BRCAPRO to extract more useful information from male relatives. Using
1500 familes from the Cancer Genetics Network, accounting for surviving other cancers improves
BRCAPRO’s concordance index from 0.758 to 0.762 (p = 0.046), improves its positive predictive
value from 35% to 39% (p < 10−6) without impacting its negative predictive value, and improves
its overall calibration, although calibration slightly worsens for those with carrier probability < 10%.
Copyright c© 2000 John Wiley & Sons, Ltd.
KEYWORDS: Mendelian Models, Competing Risks, Risk Assessment, Mendelian mutation
prediction models, BRCA1, BRCA2, MMRpro
1. Introduction
People who are concerned that their family has a high prevalence of disease may seek genetic
counseling to assess their probability of carrying inherited genetic mutations that cause
the disease [1]. To aid such people (“consultands”), genetic counselors and other medical
professionals (“genetic counselors”) employ statistical models to estimate the probability that
the consultand carries deleterious inherited mutations by using the consultand’s reported
family history of disease. For syndromes whose onset occurs over a lifetime (as is common
in cancer), family history is the age at which each family member developed disease, or that
member’s current age or age at death. The carrier probability is a crucial component in the
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consultand’s decision to take a genetic test (if a test exists), to undergo frequent disease
screening, or to consider prophylactic options.
The two major types of models that have been used are empirical models and Mendelian
models. Empirical models estimate the probability of testing positive on a genetic test, typically
using regression, with features of the given family history as predictors. Instead, Mendelian
models use Mendel’s laws and Bayes’s rule to combine family history information with each
mutation’s known prevalence and penetrance (probability of disease at an age, given mutation
status) to determine the probability that the consultand is a mutation carrier [2, 3, 4].
Mendelian models fully utilize biological laws of inheritance and use the complete family history
from all relatives, and thus can offer better predictions than empirical models [5, 6]. This paper
restricts itself to Mendelian models. An example of a Mendelian model is BRCAPRO, which
estimates the probability that a consultand carries a deleterious mutation in the BRCA1 and
BRCA2 genes, based on family history of breast and ovarian cancer [3, 7]. Another example is
MMRpro, which computes the probability of carrying a mutation in the genes MLH1, MSH2,
andMSH6, given family history of colorectal and endometrial cancer [33]. Recent methodologic
advances for Mendelian models include incorporating multiple diseases and multiple mutations
with incomplete penetrance [3], incorporating environmental risk factors [9, 10], accounting
for genetic test imperfection [11], understanding the effects of misreported family history [12],
and incorporating the effects of medical interventions [13]. This paper clarifies the independent
and non-informative censoring assumptions and proves that such censoring remains ignorable
even if people present for counseling because of a family history of disease. More importantly,
this paper extends [3] by demonstrating the impact of dependent times to diseases, the effect
of excluding diseases from the model, and that extending BRCAPRO to account for surviving
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all other cancers as a single outcome can improve BRCAPRO predictions.
Mutation prediction models must handle multiple diseases caused by mutations. We prove
that any disease unrelated to mutations can be excluded from the model, unless that disease is
both common enough and sufficiently dependent on a mutation-related disease time. However,
if the model excludes a mutation-related disease, but the family has members who were
diagnosed with it, then the carrier probability will be affected. Furthermore, we prove that
even if a family has no members with a mutation-associated disease that is excluded from the
model, then the carrier probability will be artificially inflated. Intuitively, a person surviving
all mutation-related diseases contributes evidence against carrying a mutation that should be
accounted.
We apply our results to BRCAPRO, which excludes non-breast/ovary cancers associated
with BRCA mutations. For example, pancreatic and fallopian tube cancers are associated
with BRCA mutations, and other sites may be associated as well, such as gastric, prostate, or
colorectal [14]. BRCAPRO does not account for other cancers because of uncertainty in their
association with BRCA caused by sparse data for each type of cancer. However, there is enough
data to explore an alternative model that treats surviving all other cancers as a single outcome.
This approach has the advantage of extracting information from the men in the family. We
extend BRCAPRO to account for surviving other cancers and test if it improves BRCAPRO
predictions based on 1500 families from the Cancer Genetics Network [15]. We also construct
two examples to demonstrate how strong the dependence between a mutation-unrelated disease
and breast/ovary cancer has to be so that BRCAPRO predictions are affected.
We begin by reviewing the notation, goals, and computation for Mendelian mutation
prediction models. In section 2.3, we consider the potential for informative censoring caused
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by ignoring certain mutation-related diseases or by consultands seeking counseling at young
ages due to their family history. In section 2.4 we present expressions describing the effects on
the carrier probability of ignoring a disease independent of other mutation-related diseases,
and, in section 2.5, for ignoring one dependent on other mutation-related diseases. In section 3,
we apply these results by proposing a new BRCAPRO that accounts for all non-breast/ovary
cancers, and show that this new BRCAPRO has improved discrimination and calibration.
We finish in section 3.1 by presenting two examples using BRCAPRO of including mutation-
unrelated diseases that are dependent on mutation-related diseases to illustrate the relationship
between the informativeness of including such diseases versus its prevalence and dependence.
2. Methods
2.1. Computing the Carrier Probability
Mendelian models make predictions based on knowledge of which disease each relative
developed and the age when it was diagnosed, as well as the age of censoring, that is,the
age when he or she died or the age alive after which no information is known. For example, for
BRCAPRO, the diseases are breast and ovarian cancer, and the censoring events are age at
death or last contact. Note that, although this is rare, a woman can develop both breast and
ovarian cancer in her lifetime. In this framework, everyone is eventually censored but disease
history up to that age of censoring is observed. This section sets up the notation to handle
diseases and censoring.
A Mendelian model considers D types of diseases and B causes of censoring that could
occur for each family member i (i = 0 is the consultand). Each person has a binary vector
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indicating possible censoring events bi = (bi,1, ..., bi,B) where bi,j = 1 indicates that censoring
cause j caused the censoring at age ui. Also, each person has a binary vector indicating
disease history ci = (ci,1, ..., ci,D) where ci,k = 1 indicates that disease k occurred at age yi,k
and let yi = (yi,1, ..., yi,D) be the vector of all ages of disease occurrence. Denoting censoring
information as Ui = {bi, ui} and disease information as Ti = {yi, ci}, each person’s history is
the information Hi = {Ui, Ti} and the full family history for all n+ 1 family members is the
collection H = {H0, H1, ..., Hn}.
Additionally, each person can have auxiliary variables xi and let x = {x0, x1, ..., xn}.
Auxiliaries can be any extra information known by the consultand, for example, environmental
factors, genetic test results, or ethnicity. For example, in BRCAPRO, x0 indicates if the
consultand is of Ashkenazi Jewish ancestry, an ethnic group with increased prevalence of
BRCA mutations. Implicitly, all probabilities in this paper will condition on x, so for simplicity
we only explicitly show x in the conditioning when useful.
Mendelian models for autosomal genes assume that individuals independently inherit one
allele from each parent at each autosomal locus and that the alleles are either normal or
mutated. Let γi = 0, 1 indicate carrying the genotype(s) that confer(s) disease risk: for example,
γi = 1 for a dominant trait when the member carries at least 1 mutant allele, but for a recessive
trait γi = 1 implies that the relative carries two mutant alleles. We call γi the carrier status.
The prevalence of γi = 1 amongst people with consultand-specific auxiliaries x0 is pix.
The aim of a Mendelian model is to compute the consultand’s carrier probability P (γ0 =
1|H,x). By Bayes rule, the odds of the consultand being a carrier are a product of the carrier
odds in the population and the Bayes Factor (BF):
P (γ0 = 1|H,x)
P (γ0 = 0|H,x)
=
pix
1− pix
×BF (H), where BF (H) =
P (H |γ0 = 1, x)
P (H |γ0 = 0, x)
. (1)
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The BF is a ratio of likelihoods. We compute the likelihood, assuming that each member’s
phenotype Hi is independent of all other members’ phenotypes H−i and auxiliaries x−i given
that member’s carrier status γi and auxiliary variables xi:
P (Hi|γi, xi, H−i) = P (Hi|γi, xi). (2)
Assumption (2) is a standard one for these types of calculations and has been discussed
greatly in the literature with extensive simulations investigating departures from this
assumption(c.f. [16]). The assumption is unrealistic if important risk factors are missing from
xi. The assumption could be made more realistic by including a frailty model into (3) to account
for residual familial dependence [16] or by including all known genetic and environmental risk
factors into the model [9]. However, Mendelian models are usually only employed when the
mutation confers such high disease risk (as BRCA mutations tend to) that it overwhelms the
effects of other, possibly unaccounted-for, risk factors. In this situation, departures from the
assumption are less of a concern.
The likelihood P (H |γ0, x) = P (H0|γ0, x0)P (H1, ... Hn|γ0, x) is
P (H0|γ0, x0)
1∑
γ1=0
...
1∑
γn=0
P (H1, ... Hn|γ0, ... γn, x)P (γ1, ... γn|γ0, x)
= P (H0|γ0, x0)
1∑
γ1=0
...
1∑
γn=0
(
n∏
i=1
P (Hi|γi, xi)
)
P (γ1, ... γn|γ0, x). (3)
Based on (3), the Bayes Factor in favor of γ0 = 1 is
P (H0|γ0 = 1, x0)
∑1
γ1,...,γn=0
P (γ1, ..., γn|γ0 = 1, x)
∏n
i=1 P (Hi|γi, xi)
P (H0|γ0 = 0, x0)
∑1
γ1,...,γn=0
P (γ1, ..., γn|γ0 = 0, x)
∏n
i=1 P (Hi|γi, xi)
.
Dividing top and bottom by
∏n
i=1 P (Hi|γi = 0, xi), the above is
P (H0|γ0 = 1, x0)
P (H0|γ0 = 0, x0)
×
∑1
γ1,...,γn=0
(∏n
i=1
P (Hi|γi,xi)
P (Hi|γi=0,xi)
)
P (γ1, ..., γn|γ0 = 1, x)∑1
γ1,...,γn=0
(∏n
i=1
P (Hi|γi,xi)
P (Hi|γi=0,xi)
)
P (γ1, ..., γn|γ0 = 0, x)
.
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The factors with γi = 0 cancel out, leaving only factors with γi = 1, so that is each person’s
contribution to the BF equals
P (Hi|γi = 1, xi)
P (Hi|γi = 0, xi)
. (4)
The BF contributions depend only on the likelihood contributions P (Hi|γi, xi), so we next
focus on computing these.
2.2. Computing the Likelihood Contributions: Diseases and Censoring Assumptions
For now, each person’s likelihood contribution P (Hi|γi, xi) will be computed assuming that
the times to each disease are independent given carrier status γi and auxiliaries xi. This
assumption is plausible for BRCAPRO because time to ovarian cancer and ipsi/contra-lateral
breast cancers appear to be mutually independent in BRCA mutation carriers, except for
dependence caused by medical interventions like oophorectomy [17, 18]. Interventions are
explicitly handled in another paper [13]. Auxiliaries xi can include all information necessary
to make the assumption more plausible. In section 2.5, we consider dependent diseases. As
it is possible to develop more than one cancer in a lifetime censored only by death or end
of followup, our situation is most generally described as semi-competing risks [19]. However,
developing multiple cancers is a rare occurance, even for BRCA mutation carriers.
To compute likelihood contributions, denote the density of getting each disease k at age y
given carrier status γ as fk(y|γ). This density is also known as the penetrance density. Under
independent diseases, the probability of surviving disease k to age y, is
Sk(y|γ) = 1−
∫ y
0
fk(u|γ) du. (5)
Each contribution P (Hi|γi) is the right-censored survival likelihood contribution:
P (Hi|γi) = P (Ui, Ti|γi) = P (Ui|Ti, γi)P (Ti|γi)
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
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Under independent diseases, the second factor is the product of disease-specific densities for
diseases that occurred and the disease-specific survivals for diseases that did not occur:
P (Hi|γi) = P (Ui|Ti, γi)
D∏
k=1
fk(yi,k|γi)
ci,kSk(ui|γi)
1−ci,k
∝
D∏
k=1
fk(yi,k|γi)
ci,kSk(ui|γi)
1−ci,k (6)
if the censoring is ignorable, the topic of the next section.
2.3. Implications of Independent Non-Informative Censoring
For censoring to be ignorable, it must be independent and non-informative. Independent
censoring means that all censoring events up to age t are independent of future events and so
can depend only on past events Ti that occur before age t, denoted F(t−) (see [20, Chapter 6.2]
for a formal treatment). Furthermore, under non-informative censoring, all censoring events are
independent of carrier status γi. Under these assumptions, the probability of being censored
in a small age interval [t, t+ dt), given auxiliaries, is:
P (Ui ∈ [t, t+ dt)|γi, Ti, xi) = P (Ui ∈ [t, t+ dt)|F(t−), xi). (7)
To see that these assumptions ensure that censoring is ignorable, note that in the Bayes Factor
contributions (4), by using (7), the censoring term has no γi dependence and so cancels out.
Allowing Ui to depend on past events in Ti accounts for the fact that censoring may occur as
the result of death from a mutation-related disease. If carriers and non-carriers have the same
survival to death by mutation-related disease after getting that mutation-related disease, then
equation (7) holds (where F(t−) contains the prior time to that mutation-related disease), so
this is independent non-informative censoring.
However, if mutation carriers have different survival to a terminal event compared to non-
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
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carriers, then γi remains in equation (7), and the censoring is informative. For a BRCAPRO
example, death by breast cancer would be informative of carrier status if mutation carriers
benefited from therapy after breast or ovarian cancer differently from non-carriers. One small
study suggests that women with BRCA mutations may have better survival from therapy for
ovarian cancer than non-carriers [21]. If necessary, death by mutation-related disease can be
accommodated into the likelihood contributions (6): denoting the mutation-related disease as
D, let death by it be denoted D + 1, and plug into (6) the survival SD+1(ui|γi, yi,D) and
density fD+1(ui|γi, yi,D) for death by disease D given age of diagnosis of disease D.
Informative censoring can also occur if the model does not include a mutation-related non-
terminal disease. For example, since BRCAPRO does not currently account for incidence of
pancreatic cancer (which is BRCA2 related), then censoring caused by subsequent death by
pancreatic cancer is informative censoring because mutation carriers are more likely than
non-carriers to develop pancreatic cancer and therefore to die from it (as long as pancreatic
cancer treatments don’t benefit mutation carriers more than non-carriers; we know of no such
evidence). This same problem arises when estimating penetrance [22]. This issue is avoided by
including all mutation-related diseases into the model. If informative censoring is not addressed,
the carrier probability estimate will be affected. Since pancreatic cancer is evidence in favor
of carrying a BRCA2 mutation, then ignoring censoring by it causes underestimation of the
carrier probability. However, if the unaccounted-for diseases are rare compared to other causes
of censoring (as pancreatic cancer is) or are only weakly informative (as gastric, prostate,
and colorectal cancers are likely to be), then non-informative censoring may be a reasonable
approximation.
Another important censoring issue is that if consultands seek genetic counseling at a young
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
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age before disease occurs because they are aware of their family history, then being censored
may contain information about carrier status because censoring depends on non-consultand
family history H−i. Superficially, the likelihood contributions P (Hi|γi, xi) do not appear to
condition onH−i. However, by equation (2), they do, asH−i only dropped out of the likelihood
contributions because of the assumption that phenotypes are independent given carrier status
and auxiliary variables (2). Under this assumption,
P (Ui|γi, Ti, xi) = P (Ui|γi, Ti, xi, H−i) = P (Ui|F(t−), xi, H−i).
Thus independent non-informative censoring accounts for consultands presenting based on
their family history, as long as phenotypes are independent given carrier status.
2.4. Effect of Accounting for all Independent Diseases
By excluding a disease, we mean that the mutation prediction model does not account for
it in the penetrances it uses and thus ignores that disease when it occurs in a family. Any
independent diseases that do not depend on carrier status can be safely excluded, as such
events cancel out of the Bayes Factor contributions (4) because they do not depend on γi.
Any disease that causes independent non-informative censoring, such as deaths by mutation-
unrelated causes, can be excluded for the same reason.
However, excluding a disease that does depend on carrier status affects the carrier probability
predictions. To see why, exclude disease D and let fD(y|γ = 1) > fD(y|γ = 0). Combining
equations (4) and (6), the BF contribution from disease D is a survival ratio if the person
didn’t get disease D or a density ratio if the person did get disease D. If a person in the family
is diagnosed with the excluded disease D, then the true density ratio is greater than 1, but by
excluding D, a factor of 1 is substituted. Thus, the BF contribution will be underestimated,
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
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and thus so will the carrier probability estimate. Vice-versa, if the disease occurs less often
in carriers, then the BF contribution will be overestimated. Since the BF is multiplicatively
affected, so is the carrier odds and thus the carrier probability (for small carrier probabilities).
However, even if no one in the family gets disease D, the fact that the model excludes
D will cause overestimation of the carrier probability. If fD(y|γ = 1) > fD(y|γ = 0), then
SD(y|γ = 1) < SD(y|γ = 0), and the true survival ratio is less than 1, but by excluding D, a
factor of 1 is substituted. Thus, in families where disease D does not occur, if the mutation
prediction model excludes disease D, the carrier probability is overestimated when excluding a
disease that occurs more often in carriers. Vice versa, if the disease occurs less often in carriers
and the model excludes it, then the carrier probability will be underestimated in families where
no one gets that disease. Again, since the BF is multiplicatively affected, so is the carrier odds
and thus the carrier probability (for small carrier probabilities).
It is worth noting that the same results are obtained if we only consider the first cancer
suffered by each relative (time-to-first-event pure competing risks) [23].
2.5. Dependent Diseases
Ignoring a disease that is dependent on other diseases has different effects than in the
independence case. In particular, a mutation-unrelated disease that is dependent on other
mutation-related diseases can still yield information about carrier status. By ’mutation-related’
we mean that the disease penetrance depends on carrier status. Intuitively, this happens
because the mutation-unrelated disease yields information about the time to mutation-related
disease which has direct information about carrier status.
For an example, consider the BRCAPRO example of breast cancer, ovarian cancer, and
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
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other cancers, denoted by subscripts br,ov,ot respectively. Under independence, the Bayes
Factor contribution for surviving other cancers
Sot(y|x, γ = 1)
Sot(y|x, γ = 0)
is less than 1 since other cancers are positively-mutation-related with γ = 1. Under dependence
the above factor becomes
Sot(y|Tbr, Tov, x, γ = 1)
Sot(y|Tbr, Tov, x, γ = 0)
.
For further progress, we need a model for the dependence of the times to the three outcomes.
One popular model is the positive-stable copula model [24], under which the multivariate
survival is
P (Tbr > tbr, Tov > tov, Tot > tot) = exp(−Λ
α
. ), (8)
where each disease k has cumulative hazard Λαk , Λ. =
∑
k Λk, and α ∈ (0, 1] represents the
common dependence amongst the disease times with Kendall’s τ = 1− α.
We compute the effect on the Bayes Factor of not including other cancers into the model
when a person never develops cancer. The Bayes Factor considering only breast and ovarian
cancers are
exp{−(Λbr,1 + Λov,1)
α}
exp{−(Λbr,0 + Λov,0)α}
,
where ”1” means the cumulative hazard for carriers(γ = 1) and ”0” the cumulative hazard for
non-carriers(γ = 0). The Bayes Factor including all other cancers is
exp{−(Λbr,1 + Λov,1 + Λot,1)
α}
exp{−(Λbr,0 + Λov,0 + Λot,0)α}
,
assuming that the same dependence α holds for any pair of outcomes. The ratio of these two
Bayes Factors is
R =
exp{−(Λbr,1 + Λov,1 + Λot,1)
α + (Λbr,1 + Λov,1)
α}
exp{−(Λbr,0 + Λov,0 + Λot,0)α + (Λbr,0 + Λov,0)α}
.
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Note that even if Λot,1 = Λot,0, meaning that other cancers are mutation-unrelated, this ratio
is not one. Thus a person surviving a mutation-unrelated disease can have information about
carrier status, as long that disease is dependent on mutation-related diseases. To compute
the ratio of Bayes Factors when a woman gets either breast or ovarian cancer and survives
all other cancers, one can take a derivative of the multivariate survivor function (8) to get
the expression for the density of breast or ovarian cancer jointly with surviving the other two
diseases, then compute the Bayes Factors. The ratio of Bayes Factors in this case is
(Λbr,1 + Λov,1 + Λot,1)
α−1
(Λbr,0 + Λov,0 + Λot,0)α−1
×R.
Again, even if other cancers were unrelated to mutation, this ratio is not one, implying that
there can be information by surviving diseases unrelated to mutation that are dependent on
mutation-related disease.
It is worth noting that the effect of dependency differs under different models of dependency.
For example, if instead of the positive-stable family, we chose this model of dependence:
Sot(y|Tbr, Tov, x, γ) = Sot(y|x, γ)× g(Tbr, Tov),
for some function g independent of γ, then g cancels out of the Bayes Factor. Thus, under
this model, dependency amongst diseases would not affect the Bayes Factor at all. We do not
suggest that this model of dependence applies generally, but this example emphasizes that the
effects of dependent diseases rely on the modeling of the dependency.
3. Results: Accounting for Surviving Other Cancers in BRCAPRO
As mentioned in the introduction, the current BRCAPRO does not account for surviving non-
breast/ovary cancers, because of uncertainty in their association with BRCA due to sparse data
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
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for each cancer type. However, there is enough data to estimate the penetrance of surviving all
other cancers as a single outcome independent of breast/ovary cancers in equation (6). This is
useful as many families have only breast/ovary cancers. This outcome draws information from
the men in the family, especially as prostate cancer is increasingly considered to be associated
with BRCA2 [25]. To demonstrate the importance of including surviving all other cancers into
BRCAPRO, we estimate its penetrance and then test if including it into BRCAPRO improves
mutation prediction.
To account for surviving all other cancers, we need the penetrance curves for all other
cancers. In equation (6), denote all other cancers as disease D. To estimate the penetrance
density fD(y|γ, x) at any age y by mutation status γ (0=no mutation, 1=BRCA1 mutation,
2=BRCA2 mutation) and sex (x = 0 is female, x = 1 is male), we fit a logistic curve through
the age- and sex-specific penetrance densities given in [26, Table 3] for BRCA1 mutation
carriers, and [27, Table 3] for BRCA2 mutation carriers. Using equation (5), the penetrance
survivals SD(y|γ, x) can be computed. In particular, the female penetrance survival for all other
cancers amongst BRCA1 mutation carriers is 77% by age 70; for BRCA2 mutation carriers, it
is 84%. The female non-carrier penetrance density fD(y|γ = 0, x = 1) was calculated by first
dividing the female BRCA1 carrier penetrance by the relative risk of 2.30 [26, Table 1] and
the female BRCA2 carrier penetrance by 2.45 [27, Table 1], and since these are independent
estimates of the female non-carrier penetrance, we then averaged the two (the two are not very
different). To approximate the penetrance for a person carrying both BRCA1 and BRCA2 (an
extremely rare situation), we treat their time to cancer as the minimum of the time to two
independent events: cancer due to BRCA1 and cancer due to BRCA2 (results are not sensitive
to this) [3]. For men, BRCA1 penetrances were computed using data from the same tables as
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above, for BRCA2 the data used is from [27, Table 3] summing over the prostate, pancreatic
and other cancers columns, and computing the male non-carrier penetrances used relative risks
of 1.34 [26, Table 1] and 2.45 [27, Table 1] for BRCA1 and BRCA2 respectively. In particular,
prostate cancer plays a major role in the BRCA2 penetrance estimates, as it contributes a
penetrance of 19.8% up to age 80 [27, Table 3] (recently, a specific BRCA2 mutation has been
linked to prostate cancer [25]).
Figure 1 compares the BRCAPRO BRCA2 Bayes Factor contribution (4) from a relative
when the density fD and survival SD for all other cancers are included via equation (6) into
BRCAPRO (solid lines) vs. excluded from BRCAPRO (dotted lines). Note that the dotted
lines are the Bayes Factor contributions used by the current BRCAPRO, while the solid lines
give us a sense of what the Bayes Factor contributions would be if BRCAPRO accounted for
surviving all other cancers. Figure 1 plots the Bayes Factor contributions from three possible
outcomes for a relative: breast cancer, ovarian cancer, or no cancer, with the age of those
outcomes on the x-axis. Since the density of other cancers for carriers is always greater than
that for non-carriers through age 90 (the relative risks are greater than 1), the figure confirms
that all contributions are inflated whether the person got breast or ovarian cancer, or no cancer.
The effect of excluding other cancers increases with age because its cumulative probability of
occurring becomes appreciable. Intuitively, including all other cancers properly reduces the
evidence for being a carrier by accounting for surviving all other cancers to reach old age.
Although the dotted and solid lines don’t differ much until age 70, the worst overestimation
in figure 1 is about 50% at the oldest ages. Thus excluding diseases could be a problem for
families with many relatives who developed cancer at older ages.
To see the effect on the BRCAPRO carrier probability for a family with many older relatives,
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consider figure 2. This family has only breast and ovarian cancers and could have a BRCA
mutation. If BRCAPRO excludes all other cancers, the consultand’s BRCA carrier probability
is 17%. However, if BRCAPRO includes other cancers, the carrier probability falls to 7%. The
discrepancy is large because the family’s cancers are at later ages, when the probability of
suffering other diseases by that age is appreciable. This discrepancy is critical because many
genetic counselors offer genetic testing to the consultand once the probability exceeds 10%
[28]. Also, health insurers may not cover the expense of the test unless the probability is high
enough [29].
Table I shows how the BRCAPRO carrier probability changes when BRCAPRO accounts
for all other cancers for different family histories based on figure 2. The largest discrepancies
in table I occur for the two ovarian cancer scenarios, with probabilities decreasing from 52%
to 32% and from 29% to 17%, although probably neither change would affect the decision
to offer testing. Since the presence of ovarian cancer provides the most evidence in favor
of a BRCA mutation [12], scenarios where a relative has ovarian cancer changes the carrier
probability the most. The scenarios of the mother having no cancer at 67, or the sister having
no cancer at 73, cross the 10% threshold, and so these change may well affect the decision
to offer testing. The last scenario in table I has the father dying (not due to cancer) at 67
instead of 87. The carrier probability changes from 17% to 11%, because dying at 87 has the
father survive an additional 20 years without developing cancer, and in particular, prostate
cancer, which is the biggest contributor to the penetrance of all other cancers. This shows
that accounting for surviving all other cancers helps extract information from the men in the
family tree, who usually never develop breast cancer and thus normally contribute little, if
any, information to BRCAPRO.
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To see how clinically important it is to account for surviving other cancers, we calculated
BRCAPRO carrier predictions for a subset of patients from participating centers in the
Cancer Genetics Network (CGN), described elsewhere [15]. We used 1500 consultands with
BRCA1 and BRCA2 mutation testing results and family history of breast and ovarian cancer
diagnoses. 1166 consultands were not found to carry a mutation in either gene, 226 were
BRCA1 carriers, 105 were BRCA2 carriers and 3 were carriers of mutations in both genes.
For each consultand, we calculated the BRCAPRO probabilities of carrying a mutation in
BRCA1, BRCA2 or either gene using v1.4-3 of the BayesMendel software [5]. This procedure
was then repeated, accounting for surviving all other cancers as described in this section.
We compared the discriminative abilities of BRCAPRO with and without surviving all other
cancers by using the concordance index, defined as the percent of times, among all possible
pairs of carriers and noncarriers, that an individual testing positive for deleterious mutations
of either BRCA1 or BRCA2 has the higher carrier probability: a value of 0 represents
perfect discordance in the model, 1 represents perfect prediction, and 0.5 represents chance
prediction [30, 31].
The results are in table II. The concordance index for any BRCA mutation in the original
BRCAPRO was estimated at 0.758, and for BRCAPRO accounting for surviving other cancers,
0.762 (p = 0.046). Thus there is a slight improvement by accounting for surviving other cancers.
In particular, when restricting to BRCA1 mutations, the conconcordance index only goes from
0.7796 to 0.7798, but for BRCA2 mutations, it increases from 0.689 to 0.696. The improvement
is greatest for predicting BRCA2 mutations, as may be expected since the most important
other cancer taken into account is prostate cancer in BRCA2 carriers.We then use the standard
10% carrier probability threshold for making carrier status predictions. Since accounting for
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surviving other cancers can only decrease the carrier probability, the sensitivity decreases
somewhat when accounting for surviving other cancers, but is offset by a greater increase in
specificity (table II). Most importantly from the point of view of a consultand, table II shows
that accounting for surviving other cancers does not affects the negative predictive value, yet
increases the overall positive predictive value of BRCAPRO from 35% to 39% (p < 10−6).
The calibration of the models was checked by computing the ratio of the observed number
of mutation carriers to the number of carriers expected under each model (O/E). An O/E = 1
implies that the model is well-calibrated; an O/E < 1 implies that the model over-predicts
and vice-versa for O/E > 1. For the entire dataset, BRCAPRO excluding surviving all
other cancers tends to over-predict, especially BRCA2 mutations (Table III). The BRCAPRO
including surviving all other cancers improves overall calibration. However, improvement is
confined to those with carrier probabilities > 10%; for those < 10%, including all other cancers
worsens calibration.
3.1. Dependent Diseases
As section 2.5 showed, mutation-unrelated diseases dependent on mutation-related diseases can
carry information about carrier status. In this section, we present two examples to illustrate
when it may be worthwhile to consider including such a disease in the model. The examples
are based on BRCAPRO: in the first, let the disease be endometrial cancer (a rare disease
that shares many of the same risk factors as breast and ovarian cancer), in the second, let the
disease be diabetes (a common disease that shares far fewer risk factors with breast and ovarian
cancer) [32]. Neither disease is related to BRCA mutations; endometrial cancer is rarer than
diabetes, but likely to have a stronger dependence on breast/ovarian cancer than diabetes. The
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ratio of Bayes Factors in section 2.5 depends on both the prevalence of the disease and the
strength of its association with mutation-related diseases. The age-specific risk for endometrial
cancer is taken from the general population [8] and that for diabetes is taken from a logistic
curves fit through tables 1 and 2 of [34].
We assume the positive-stable copula model for each of endometrial cancer and diabetes with
breast and ovarian cancers, and try a few hypothetical but plausible choices of Kendall’s τ to
illustrate how much dependence on breast/ovarian cancers is needed to affect the Bayes Factors
of section 2.5 (figure 3). For endometrial cancer, if Kendall’s τ = 0.2, there is little change
the to Bayes Factors depending on whether endometrial cancer is included (+17% maximum
change) until τ increases to 0.5 (figure 3). Since the lifetime risk of endometrial cancer is only
3%, weak dependence does not importantly affect the Bayes Factors. For diabetes, if Kendall’s
τ is 0.05, there is little effect on the Bayes Factors (+13% maximum change) until τ is increased
to 0.2 (figure 3). Since the lifetime risk of diabetes is 30%, less dependence is needed affect the
Bayes Factors. For both diseases, the amount of dependence necessary to change the Bayes
Factors using a positive-stable copula is probably much larger than is realistic, and so does
not warrant consideration for inclusion into BRCAPRO.
4. Discussion
This paper clarifies the role of the independent and non-informative censoring assumption in
Mendelian modeling of carrier probabilities and proves that such censoring remains ignorable
even if people present for counseling because of a family history of disease. More importantly,
we extended [3] in three ways.We demonstrated that mutation-unrelated diseases dependent on
mutation-related diseases can still provide information about mutation status, if the mutation-
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unrelated diseases are prevalent enough and have strong enough dependence on mutation-
related diseases. We demonstrated that excluding mutation-related diseases from the model,
when all family members survive all excluded diseases, deflates the carrier probability. We
extended BRCAPRO to account for surviving all other cancers, combining these into a a
single outcome and showed that this improves BRCAPRO’s concordance index and its positive
predictive value with no impact on its negative predictive value. This extension also improves
the over-prediction of BRCAPRO both overall and for those with carrier probability > 10%,
although worsening the under-prediction seen at carrier probabilities < 10%.
The improvement in discriminatory power to BRCAPRO occurs for two reasons. One,
incorporating surviving all other cancers helps extract information from the men in the family,
who almost always survive breast cancers (even among carriers), and so usually contribute
little, if any, information. The improvement is mostly for predicting BRCA2 mutations, for
which surviving prostate cancer is important information. Second, surviving all other cancers
appropriately discounts the carrier probability in families where many relatives survive to old
ages, especially in families with many older relatives with cancer. Genetic counselors should
be aware of this effect when considering such families.
Since including surviving all other cancers always decreases the carrier probability, it
naturally corrects for over-prediction but exacerbates under-prediction. Thus BRCAPRO over-
predicting both overall and for those with carrier probability > 10% is naturally mitigated, but
the under-prediction for those with carrier probability < 10% can only be worsened. Again,
the biggest effect is seen for predicting BRCA2 mutations.
Our results demonstrate that accounting for all other cancers improves the performance of
BRCAPRO and points to the importance of extending BRCAPRO to account for each type of
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non-breast/ovary cancer. However, this extension at a level of accuracy adequate for clinical use
is beyond the scope of this paper as it requires that the penetrance of each disease be reliably
estimated. This estimation can be challenging when existing studies do not report a sufficient
number of people with each disease. Although there are many studies looking for associations
of BRCA mutations with other cancers [14], each study averages less than 5 cancers per site.
A sensible option is to pool mutation-related diseases together to get a favorable bias-variance
tradeoff, as the category of all other cancers tries to do. Ideally, all other cancers should include
only mutation-related cancers, unless a mutation-unrelated disease is common enough and has
strong enough dependence on a mutation-related disease (for BRCAPRO, we are not aware of
any such disease). The next step is to try to account for all the above issues in a meta-analysis
of all available data to produce reliable penetrance estimates for a carefully chosen set of other
cancers likely to be associated with BRCA mutations.
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Excluding non- Including non-
Family breast/ovary cancers breast/ovary cancers
As in Figure 1 17% 7%
Mother has only ovarian cancer at 67 29% 17%
Mother has no cancer at 67 15% 6%
Sister has only ovarian cancer at 73 52% 32%
Sister has no cancer at 73 11% 5%
Father died at 67 instead of 87 17% 11%
Table I. Effect on the BRCAPRO carrier probability of excluding vs. including all non-breast/ovary
cancers into BRCAPRO for families based on figure 1. Non-breast/ovary cancers are included as per
the methods of section 2.4.
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Predicting Predicting Predicting
BRCA1 or BRCA2 BRCA1 BRCA2
Excluding Including p Excluding Including p Excluding Including p
Concordance 0.758 0.762 0.046 0.7796 0.7798 0.90 0.689 0.696 0.18
PPV 35% 39% < 10−6 41% 44% < 10−6 38% 43% < 10−6
NPV 90% 90% 0.86 88% 88% 0.94 85% 84% 0.91
Sensitivity 77% 74% < 10−6 65% 62% 0.002 55% 46% < 10−6
Specificity 58% 67% < 10−6 73% 77% < 10−6 74% 83% < 10−6
Table II. Characteristics of the BRCAPRO predictions that exclude surviving all non-breast/ovary
cancers versus including surviving all non-breast/ovary cancers. The first three columns are for
predicting BRCA1 or BRCA2 mutations, the second for predicting solely BRCA1 mutations, the third
column for predicting solely BRCA2 mutations. The postive/negative predictive values (PPV,NPV),
sensitivity, and specificity are all for a 10% carrier probability threshold. The p-value column tests if
the difference between including and excluding is zero for each statistic.
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Predicting Predicting Predicting
BRCA1 or BRCA2 BRCA1 BRCA2
Excluding Including Excluding Including Excluding Including
Overall O/E 0.87 1.01 0.95 1.04 0.72 0.94
Left 95% 0.79 0.93 0.85 0.93 0.59 0.77
Right 95% 0.95 1.10 1.06 1.16 0.86 1.12
<10% O/E 3.2 3.8 2.9 3.4 1.4 1.8
Left 95% 2.6 3.0 2.2 2.7 1.0 1.4
Right 95% 4.0 4.6 3.6 4.2 1.9 2.4
>10% O/E 0.72 0.80 0.75 0.78 0.52 0.62
Left 95% 0.65 0.73 0.66 0.69 0.41 0.47
Right 95% 0.79 0.88 0.84 0.88 0.65 0.78
Table III. Calibration of the BRCAPRO predictions that exclude surviving all non-breast/ovary cancers
versus including surviving all non-breast/ovary cancers. The first two columns are for predicting
BRCA1 or BRCA2 mutations, the second for predicting solely BRCA1 mutations, the third for
predicting solely BRCA2 mutations. The rows are for all the data (overall), those with carrier
probability < 10%, and with carrier probability > 10%, computing the ratio of observed to expected
(O/E) and the left/right endpoints of its 95% confidence interval.
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Figure 1. Effect of excluding and including all non-breast/ovary cancers as a competing risk on the
contributions to the Bayes Factor in favor of carrying a BRCA2 mutation. The penetrance for all
other cancers by BRCA2 carrier status is from The Breast Cancer Linkage Consortium, 1999. Dotted
lines exclude all other cancers, solid lines include it.
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Figure 2. Family Tree with Breast (Br) and Ovarian (Ov) cancer history. The arrow points to the
consultand. Circles are females, squares are males. Slash means the relative died, dark shape means
the relative got cancer, light shape and no slash means the relative is alive with no cancer, and the
age of those outcomes is below each member.
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Figure 3. Effect of excluding and including diabetes (left panel) or endometrial cancer (right panel)
as a disease on the contributions to the Bayes Factor in favor of carrying a BRCA1 mutation. Dotted
lines exclude the disease for the panel, solid lines include it. For both panels, the upper pair of lines
is for the relative getting breast cancer, the bottom pair is for surviving all diseases.
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